← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

BridgeBio Pharma, Inc. (BBIO) 10-Year Financial Performance & Capital Metrics

BBIO •
HealthcareBiotechnologyCommercial Rare Disease Biopharma
AboutBridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.Show more
  • Revenue $502M +126.3%
  • EBITDA -$560M +4.6%
  • Net Income -$729M -36.1%
  • EPS (Diluted) -3.79 -31.6%
  • Gross Margin 94.37% -4.0%
  • EBITDA Margin -111.55% +57.8%
  • Operating Margin -113.35% +57.6%
  • Net Margin -145.26% +39.8%
  • ROE -
  • ROIC -
  • Debt/Equity -
  • Interest Coverage -10.72 -79.4%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Strong 5Y sales CAGR of 127.4%

✗Weaknesses

  • ✗Weak Piotroski F-Score: 3/9
  • ✗Negative free cash flow

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y127.44%
3Y86.3%
TTM126.26%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-36.13%

EPS CAGR

10Y-
5Y-
3Y-
TTM-32.98%

ROCE

10Y Avg-80.14%
5Y Avg-93.68%
3Y Avg-105.5%
Latest-80.55%

Peer Comparison

Commercial Rare Disease Biopharma
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
CORTCorcept Therapeutics Incorporated3.78B35.7043.5412.79%13.01%15.3%3.75%0.01
BMRNBioMarin Pharmaceutical Inc.11.86B61.7334.2910.83%5.73%6.11%0.10
VRTXVertex Pharmaceuticals Incorporated126.19B496.8332.438.9%31.35%21.22%2.53%0.20
CPRXCatalyst Pharmaceuticals, Inc.2.83B23.0813.7419.78%36.39%22.46%7.38%0.00
HRMYHarmony Biosciences Holdings, Inc.1.65B28.5410.5321.51%18.27%18.24%21.12%0.02
PTCTPTC Therapeutics, Inc.5.45B68.198.76114.51%42.25%
BCRXBioCryst Pharmaceuticals, Inc.1.86B8.757.2394.1%30.16%18.63%
RAREUltragenyx Pharmaceutical Inc.2.26B23.39-3.7229.01%-91.95%-35.88%0.15

Compare BBIO vs Peers

Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.

vs AGIO

Compare head-to-head with Agios Pharmaceuticals, Inc.

vs VRTX

Compare head-to-head with Vertex Pharmaceuticals Incorporated

Compare Top 5

vs AGIO, VRTX, ASND, BMRN

Profit & Loss

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Sales/Revenue+0040.56M8.25M69.72M77.65M9.3M221.9M502.08M
Revenue Growth %----79.66%745.14%11.38%-88.02%2285.27%126.26%
Cost of Goods Sold+260K02.5M03.11M3.43M2.45M3.88M28.27M
COGS % of Revenue--6.16%-4.47%4.42%26.29%1.75%5.63%
Gross Profit+-260K038.06M8.25M66.6M74.21M6.86M218.02M473.81M
Gross Margin %--93.84%100%95.53%95.58%73.71%98.25%94.37%
Gross Profit Growth %-100%--78.33%707.39%11.43%-90.76%3079.58%117.32%
Operating Expenses+43.86M183.66M304.3M482.73M643.23M586.42M614.23M811M1.04B
OpEx % of Revenue--750.25%5851.99%922.65%755.22%6602.46%365.48%207.72%
Selling, General & Admin13.3M43.59M94.35M145.68M192.21M143.19M150.59M288.93M555.14M
SG&A % of Revenue--232.63%1766.08%275.7%184.41%1618.73%130.21%110.57%
Research & Development30.56M140.07M209.95M337.05M451.02M399.46M455.71M506.46M477.54M
R&D % of Revenue--517.62%4085.91%646.94%514.45%4898.54%228.24%95.11%
Other Operating Expenses0000043.77M7.93M15.61M10.22M
Operating Income+-43.86M-183.66M-266.24M-474.48M-576.63M-512.2M-607.37M-592.97M-569.09M
Operating Margin %---656.41%-5751.99%-827.12%-659.65%-6528.75%-267.22%-113.35%
Operating Income Growth %--318.76%-44.96%-78.22%-21.53%11.17%-18.58%2.37%4.03%
EBITDA+-43.6M-183.41M-265.38M-473.03M-570.79M-505.43M-600.88M-586.9M-560.09M
EBITDA Margin %---654.29%-5734.34%-818.73%-650.93%-6458.95%-264.49%-111.55%
EBITDA Growth %--320.7%-44.69%-78.24%-20.67%11.45%-18.88%2.33%4.57%
D&A (Non-Cash Add-back)260K245K859K1.46M5.84M6.77M6.49M6.08M9M
EBIT-43.82M-183.66M-279.82M-468.83M-539.68M-404.21M-571.96M-442.9M-681.88M
Net Interest Income+26K-543K150K-32.64M-45.65M-72.9M-63.25M-82.04M-33.25M
Interest Income39K2M8.91M4.01M1.13M7.54M18.04M17.25M19.85M
Interest Expense13K2.55M8.77M36.66M46.78M80.44M81.29M99.29M53.1M
Other Income/Expense26K14.21M-22.34M-31.01M-9.82M27.55M-45.88M50.78M-165.9M
Pretax Income+-43.83M-169.45M-288.58M-505.49M-586.45M-484.65M-653.25M-542.19M-734.99M
Pretax Margin %---711.5%-6127.87%-841.2%-624.17%-7021.94%-244.34%-146.39%
Income Tax+00000001.15M555K
Effective Tax Rate %69.73%77.16%90.25%88.77%95.92%99.28%98.46%98.81%99.23%
Net Income+-30.57M-130.75M-260.44M-448.72M-562.54M-481.18M-643.2M-535.76M-729.31M
Net Margin %---642.1%-5439.74%-806.9%-619.7%-6913.92%-241.44%-145.26%
Net Income Growth %--327.77%-99.19%-72.3%-25.36%14.46%-33.67%16.7%-36.13%
Net Income (Continuing)-43.83M-169.45M-288.58M-505.49M-586.45M-484.65M-653.25M-543.35M-735.54M
Discontinued Operations000000000
Minority Interest3.33M62.48M67.52M49.98M4.83M9.69M11.72M10.29M-570K
EPS (Diluted)+-0.33-1.42-2.48-4.10-3.90-3.35-3.95-2.88-3.79
EPS Growth %--330.3%-74.65%-65.32%4.88%14.1%-17.91%27.09%-31.6%
EPS (Basic)-0.33-1.42-2.48-4.10-3.90-3.35-3.95-2.88-3.79
Diluted Shares Outstanding92.33M92.33M105.1M118M144.36M147.47M162.79M186.08M197.24M
Basic Shares Outstanding92.33M92.33M105.1M118M144.36M147.47M162.79M186.08M197.24M
Dividend Payout Ratio---------

Balance Sheet

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Current Assets+97.13M445.22M568.62M642.82M888.86M548.85M477.59M720.69M753.68M
Cash & Short-Term Investments92M436.09M545.99M607.09M836.66M471.92M434.88M681.1M587.48M
Cash Only92M436.09M363.77M356.08M393.77M376.69M375.94M681.1M570.12M
Short-Term Investments00182.22M251.01M442.89M95.23M58.95M0587.48M
Accounts Receivable002.85M019.75M17.08M1.75M4.72M139.44M
Days Sales Outstanding--25.6-103.480.2868.77.77101.37
Inventory0000000026.75M
Days Inventory Outstanding--------345.38
Other Current Assets889K00139K177K37.93M27.65M3.83M0
Total Non-Current Assets+913K19.72M63.06M60.76M123.93M74.18M68.79M198.65M41.59M
Property, Plant & Equipment440K1.57M5.63M36.83M45.97M25.25M19.84M12.78M13.52M
Fixed Asset Turnover--7.21x0.22x1.52x3.08x0.47x17.37x37.15x
Goodwill000000000
Intangible Assets000044.93M28.71M26.32M23.93M28.08M
Long-Term Investments381K17.05M31.14M0000143.75M0
Other Non-Current Assets92K1.09M26.29M23.93M33.03M20.22M22.63M18.2M0
Total Assets+98.04M464.94M631.68M703.59M1.01B623.04M546.38M919.34M936.02M
Asset Turnover--0.06x0.01x0.07x0.12x0.02x0.24x0.54x
Asset Growth %-374.22%35.86%11.38%43.95%-38.48%-12.3%68.26%1.82%
Total Current Liabilities+8.55M32.58M60.38M95.65M135.07M121.43M143.84M154.4M287.97M
Accounts Payable1.89M13.51M8.85M8.95M11.88M11.56M10.65M9.62M36.23M
Days Payables Outstanding2.65K-1.29K-1.39K1.23K1.59K905.25467.7
Short-Term Debt0001.46M00006.19M
Deferred Revenue (Current)000008.16M6.1M020.27M
Other Current Liabilities997K4.01M25.39M9.55M37.04M31.26M65.59M16.2M225.28M
Current Ratio11.36x13.67x9.42x6.72x6.58x4.52x3.32x4.67x2.62x
Quick Ratio11.36x13.67x9.42x6.72x6.58x4.52x3.32x4.67x2.52x
Cash Conversion Cycle---------20.95
Total Non-Current Liabilities+144.18M533.87M95.32M500.05M1.74B1.75B1.75B2.22B2.72B
Long-Term Debt143.87M54.51M91.79M475.86M1.7B1.71B1.73B1.72B3.81M
Capital Lease Obligations00014.68M17.43M12.27M8.98M4.7M0
Deferred Tax Liabilities000000000
Other Non-Current Liabilities312K479.36M3.53M9.52M22.07M26.64M9.36M496.47M2.72B
Total Liabilities152.73M566.44M155.7M595.7M1.88B1.87B1.89B2.38B3.01B
Total Debt+143.87M54.51M91.79M495.79M1.73B1.72B1.74B1.73B10M
Net Debt51.87M-381.58M-271.98M139.71M1.33B1.35B1.36B1.05B-560.12M
Debt / Equity--0.19x4.60x-----
Debt / EBITDA---------
Net Debt / EBITDA---------
Interest Coverage-3373.69x-72.11x-30.38x-12.94x-12.33x-6.37x-7.47x-5.97x-10.72x
Total Equity+-54.69M-101.5M475.98M107.89M-865.58M-1.24B-1.34B-1.46B-2.08B
Equity Growth %--85.61%568.93%-77.33%-902.31%-43.83%-7.84%-8.57%-42.5%
Book Value per Share-0.59-1.104.530.91-6.00-8.44-8.25-7.83-10.53
Total Shareholders' Equity-58.02M-163.99M408.45M57.91M-870.41M-1.25B-1.35B-1.47B-2.08B
Common Stock3.41M6.59M124K125K154K157K181K196K202K
Retained Earnings-61.43M-170.58M-440.03M-888.75M-1.44B-1.92B-2.56B-3.1B-3.82B
Treasury Stock000-75M-275M-275M-275M-275M0
Accumulated OCI-27K-231K254K192K-132K-328K31K8K12K
Minority Interest3.33M62.48M67.52M49.98M4.83M9.69M11.72M10.29M-570K

Cash Flow

Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Cash from Operations+-40.49M-136.64M-253.59M-399.71M-497.93M-419.49M-527.72M-520.73M-445.91M
Operating CF Margin %---625.21%-4845.61%-714.23%-540.25%-5672.58%-234.66%-88.81%
Operating CF Growth %--237.49%-85.58%-57.62%-24.57%15.75%-25.8%1.33%14.37%
Net Income-43.83M-169.45M-288.58M-505.49M-586.45M-484.65M-643.2M-543.35M-724.93M
Depreciation & Amortization260K245K859K3.09M5.84M6.77M6.49M6.08M5.97M
Stock-Based Compensation1.84M6.07M21.37M58.46M99.5M91.56M095.8M133.02M
Deferred Taxes-260K-14.89M-859K-1.87M-30.93M0000
Other Non-Cash Items260K18.89M24.54M31.16M18.5M-61.25M103.93M-111.3M140.03M
Working Capital Changes1.24M22.49M-10.91M14.93M-4.4M28.08M5.06M32.04M0
Change in Receivables00-2.85M2.85M-19.75M15.17M15.33M-2.97M-134.72M
Change in Inventory002.85M-2.85M19.75M000-25.31M
Change in Payables1.58M16.7M-4.66M-735K2.83M-349K2.78M1.51M26.61M
Cash from Investing+-464K-21.04M-217.25M-52.99M-200.83M453.15M54.03M60.78M-24.49M
Capital Expenditures-464K-18.18M-5.14M-7.52M-48.25M-4.82M-1.31M-933K-1.1M
CapEx % of Revenue--12.67%91.14%69.2%6.21%14.04%0.42%0.22%
Acquisitions2.84M-2.86M-5.49M21.24M-35M00-140K0
Investments---------
Other Investing0-2.86M784K-21.09M48.65M118.5M-503K-7.97M-6.19M
Cash from Financing+112.98M501.55M398.79M447.19M736.45M-13.13M451.54M748.46M359.29M
Debt Issued (Net)4.13M56.38M36.94M550M1.08B-20.49M0476.58M0
Equity Issued (Net)1000K1000K1000K-1000K-1000K1000K1000K1000K0
Dividends Paid-1.15M0-997K000000
Share Repurchases000-75.71M-204.75M-1.56M-6.88M-7.53M-48.28M
Other Financing1.83M14.64M-4.38M-27.1M-138.49M4.06M8.61M-35.34M359.29M
Net Change in Cash72.03M343.87M-72.05M-5.52M37.69M20.52M-22.15M288.51M-111.1M
Free Cash Flow+-40.95M-154.82M-258.73M-407.23M-546.18M-425.81M-529.03M-521.66M-447.01M
FCF Margin %---637.88%-4936.74%-783.44%-548.39%-5686.62%-235.09%-89.03%
FCF Growth %--278.05%-67.11%-57.4%-34.12%22.04%-24.24%1.39%14.31%
FCF per Share-0.44-1.68-2.46-3.45-3.78-2.89-3.25-2.80-2.27
FCF Conversion (FCF/Net Income)1.32x1.05x0.97x0.89x0.89x0.87x0.82x0.97x0.61x
Interest Paid0000054.44M61.11M00
Taxes Paid000000000

Key Ratios

Metric201720182019202020212022202320242025
Return on Equity (ROE)---139.1%-153.71%-----
Return on Invested Capital (ROIC)----157.61%-121.07%-135.08%-738.78%--
Gross Margin--93.84%100%95.53%95.58%73.71%98.25%94.37%
Net Margin---642.1%-5439.74%-806.9%-619.7%-6913.92%-241.44%-145.26%
Debt / Equity--0.19x4.60x-----
Interest Coverage-3373.69x-72.11x-30.38x-12.94x-12.33x-6.37x-7.47x-5.97x-10.72x
FCF Conversion1.32x1.05x0.97x0.89x0.89x0.87x0.82x0.97x0.61x
Revenue Growth----79.66%745.14%11.38%-88.02%2285.27%126.26%

Deep Dive Analysis

Explore detailed financial history, valuation models, and returns analysis

Valuation Overview

DCF models, peer multiples & analyst estimates

Total Return Calculator

Historical returns with dividends reinvested

Dividend History

Yield, growth, payout safety & DRIP calculator

Earnings History

EPS trends, net income & profitability analysis

Price History

Long-term charts & historical price data

Revenue History

Sales growth patterns & revenue breakdown

Financial Ratios

30 years of valuation, profitability & efficiency metrics

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.